Scholarlink

Objectives <p><i>Campylobacter jejuni</i> is a leading cause of bacterial gastroenteritis but rarely causes bacteraemia, except in immunocompromised hosts. Carbapenem resistance in <i>C. jejuni</i> remains uncommon, and the clinical evolution of resistance during infection has not been well described.</p> Methods <p>We report a case series of three immunocompromised adults with recurrent <i>C. jejuni</i> bacteraemia at a tertiary hospital in Singapore between 2024 and 2025.</p> Results <p>All three patients had underlying haematologic or autoimmune disorders associated with hypogammaglobulinaemia. Each experienced multiple episodes of <i>C. jejuni</i> bacteraemia despite prolonged carbapenem therapy, with isolates showing stepwise increases in meropenem minimum inhibitory concentrations (MICs) from ≤ 0.05&#xa0;mg/L to as high as 16&#xa0;mg/L. No abscesses or drainable foci were identified radiologically. Two patients received regular intravenous immunoglobulin (IVIG) replacement after low serum IgG levels were detected. In all cases, recurrences ceased after introduction of eravacycline therapy, with or without concurrent oral gentamicin, in combination with IVIG support. One patient later died of progression of underlying lymphoma.</p> Conclusions <p>This series demonstrates the potential for acquired carbapenem resistance to develop in <i>C. jejuni</i> during recurrent bacteraemia in immunocompromised hosts. Eravacycline, alongside immunoglobulin replacement, may represent a viable therapeutic option in such refractory infections.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Recurrent Campylobacter jejuni bacteraemia with independent acquisition of carbapenem resistance in three ST9611 isolates: a case series in immunocompromised hosts

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月9日

查看全文
  • Jinghao Nicholas Ngiam,
  • Matthew Chung Yi Koh,
  • Grace Tung,
  • Fengjie Tang,
  • Jeanette Teo,
  • Ka Lip Chew

摘要

Objectives

Campylobacter jejuni is a leading cause of bacterial gastroenteritis but rarely causes bacteraemia, except in immunocompromised hosts. Carbapenem resistance in C. jejuni remains uncommon, and the clinical evolution of resistance during infection has not been well described.

Methods

We report a case series of three immunocompromised adults with recurrent C. jejuni bacteraemia at a tertiary hospital in Singapore between 2024 and 2025.

Results

All three patients had underlying haematologic or autoimmune disorders associated with hypogammaglobulinaemia. Each experienced multiple episodes of C. jejuni bacteraemia despite prolonged carbapenem therapy, with isolates showing stepwise increases in meropenem minimum inhibitory concentrations (MICs) from ≤ 0.05 mg/L to as high as 16 mg/L. No abscesses or drainable foci were identified radiologically. Two patients received regular intravenous immunoglobulin (IVIG) replacement after low serum IgG levels were detected. In all cases, recurrences ceased after introduction of eravacycline therapy, with or without concurrent oral gentamicin, in combination with IVIG support. One patient later died of progression of underlying lymphoma.

Conclusions

This series demonstrates the potential for acquired carbapenem resistance to develop in C. jejuni during recurrent bacteraemia in immunocompromised hosts. Eravacycline, alongside immunoglobulin replacement, may represent a viable therapeutic option in such refractory infections.